S1 |
(MH “Immunologic Deficiency Syndromes+”) |
71,189 |
S2 |
(MH “Human Immunodeficiency Virus+”) |
6,682 |
S3 |
(immunodeficien∗ OR PIDD OR PIDDs OR PID OR PIDs OR SID OR SIDs) |
29,272 |
S4 |
(HIV OR AIDS OR XLA OR CVID) |
110,135 |
S5 |
(agammaglobulin#emi∗ OR agamma globulin#emi∗ OR Hypogammaglobulin#emi∗ OR Hypogamma globulin#emi∗ OR hypo gammaglobulin#emi∗ OR hypo gamma globulin#emi∗ OR hypo IgG OR hypergammaglobulin#emi∗ OR hypergamma globulin#emi∗ OR hyper gammaglobulin#emi∗ OR hyper gamma globulin#emi∗ OR Hyperimmunoglobulin∗ OR hyper immunoglobulin∗ OR hyper IgM OR HIGM OR hyper IgE OR HIES OR hyper IgD OR HIDS OR hypoimmunoglobulin#emi∗ OR hypo immunoglobulin#emi∗ OR Dysgammaglobulin#emi∗) |
967 |
S6 |
((Tcell OR T cell OR Bcell OR B cell OR TBcell OR TB cell OR Adenosine deaminase OR ZAP70 OR immune OR immuno OR immunity OR immunologic∗ OR antibody OR immunoglobulin∗ OR immune globulin∗ OR gammaglobulin OR gamma globulin OR IgG OR IgA OR Leukocyte-Adhesion) N2 (deficien∗ OR defect∗ OR disorder∗)) |
3,887 |
S7 |
((immun∗ OR idiopathic OR purpura) N2 thrombocytopeni∗) |
2,008 |
S8 |
S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 |
120,895 |
S9 |
(MH “Immunoglobulins”) |
11,680 |
S10 |
(MH “Immunoglobulins, Intravenous”) |
1,775 |
S11 |
(MH “Immunotherapy”) |
4,714 |
S12 |
(MH “Gamma Globulins”) |
139 |
S13 |
S9 OR S10 OR S11 OR S12 |
17,916 |
S14 |
(MH “Injections, Subcutaneous+”) |
3,195 |
S15 |
(MH “Infusions, Subcutaneous”) |
658 |
S16 |
(subcutaneous∗ OR “sub cutaneous” OR “sub cutaneously”) |
14,850 |
S17 |
S14 OR S15 OR S16 |
14,938 |
S18 |
S13 AND S17 |
373 |
S19 |
((subcutaneous∗ OR “sub cutaneous” OR “sub cutaneously”) N6 (immunoglobulin∗ OR Ig OR IgG OR immune globulin∗ OR gammaglobulin OR gammaglobulins OR gamma globulin OR gamma globulins OR immunotherap∗ OR immune therap∗ OR Gamunex∗ OR Gammagard∗ OR Subcuvia∗ OR Endobulin∗ OR Privigen∗ OR Nordimmun∗ OR Gammaplex∗ OR Octagam∗ OR Gammanorm∗ OR KIOVIG∗)) |
297 |
S20 |
(SCIG OR SCIGG OR SC IG OR SC IGG OR IGSC) |
33 |
S21 |
(Hizentra∗ OR IgPro20∗ OR Vivaglobin∗ OR Beriglobin∗ OR Evogam∗ OR Gammabulin∗ OR HYQVIA∗ OR IGHy OR Subgam∗) |
19 |
S22 |
S18 OR S19 OR S20 OR S21 |
520 |
S23 |
S8 AND S22 |
77 |
S24 |
S23 |
76 |
S25 |
(MH “Economics”) |
11,303 |
S26 |
(MH “Economic Aspects of Illness”) |
6,876 |
S27 |
(MH “Economic Value of Life”) |
521 |
S28 |
MH “Economics, Dental” |
109 |
S29 |
MH “Economics, Pharmaceutical” |
1,795 |
S30 |
MW “ec” |
144,148 |
S31 |
(econom∗ or price or prices or pricing or priced or discount∗ or expenditure∗ or budget∗ or pharmacoeconomic∗ or pharmaco-economic∗) |
221,952 |
S32 |
(MH “Costs and Cost Analysis+”) |
86,622 |
S33 |
TI cost∗ |
40,864 |
S34 |
(cost effective∗) |
29,781 |
S35 |
AB (cost∗ N2 (util∗ or efficacy∗ or benefit∗ or minimi∗ or analy∗ or saving∗ or estimate∗ or allocation or control or sharing or instrument∗ or technolog∗)) |
20,585 |
S36 |
(decision N1 (tree∗ or analy∗ or model∗)) |
5,381 |
S37 |
(markov or markow or monte carlo) |
3,537 |
S38 |
(MH “Quality-Adjusted Life Years”) |
2,782 |
S39 |
(QOLY or QOLYs or HRQOL or HRQOLs or QALY or QALYs or QALE or QALEs) |
6,703 |
S40 |
((adjusted N1 (quality or life)) or (willing∗ N2 pay) or sensitivity analys?s) |
12,555 |
S41 |
S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 |
296,935 |
S42 |
S24 AND S41 |
16 |
S43 |
S24 AND Limiters – English Language |
16 |